drugset / Trial / NCT05273541

Safety and Immunogenicity of Prime-boost Vaccination of SARS-CoV-2 in Patients With Cancer

NCT05273541 ↗

Phase 1/2 Unknown 100 enrolled Beijing 302 Hospital
NaSingle-groupOpen-labelTreatment

Summary

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has caused a global pandemic since late 2019 that resulted in more than 360 million population infection. Patients with cancers may be at higher risk of infection and severity than those without cancer. Mass vaccination has been carried out, but reinfection and vaccine breakthrough cases still occur. Now, the prime-boost regimen was identified safe and efficient, but the reactogenicity and immunogenicity of prime-boost vaccine strategy in cancer patients were not known.

Timeline

Start
2022-02-11
Primary completion
2022-12-30
Completion
2023-07-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Coronavirus vaccination Vaccine — —

Indications